Mode
Text Size
Log in / Sign up
Phase 3 N=173 Randomized Quadruple-blind Treatment

Premedication Trial for Tracheal Intubation of the NEOnate

Premedication · Endotracheal Intubation

Enrolled (actual)
173
Serious AEs
15.3%
Results posted
Sep 2019
Primary outcome: Primary: Number of Patients With Prolonged Desaturation — 54; 53 Participants — p=0.38

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
atropine+ propofol (Drug); atropine + atracurium + sufentanil (Drug)
Age
Pediatric
Sex
All
Sponsor
Centre Hospitalier Intercommunal Creteil
Primary completion
Aug 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients With Prolonged Desaturation
54; 53 0.38
SECONDARY
Number of Intubation Attempts
41; 47; 25; 23; 21; 11
SECONDARY
Duration of Intubation Procedure
6.0; 3.5
SECONDARY
Heart Rate
3.3; 11.5; 1.6; 11.7
SECONDARY
Short Term Neurological Outcome: Worsening of Head Ultrasound
14; 12
SECONDARY
Number of Patients Surviving Without Ages and Stages Questionnaire Score Below Threshold at Age 2
38; 45
SECONDARY
Pulse Oxymetry
-6.0; -12.0; -8.7; -15.9
SECONDARY
Mean Blood Pressure
-6.8; 0.2; -9.1; -3.3
SECONDARY
Transcutaneous PCO2 (TcPCO2) Measurement
8.0; 14.1; 5.1; 16.2

Summary

Multicenter double blind randomized controlled trial comparing "atropine+propofol" vs "atropine+atracurium+sufentanil" as a premedication prior to endotracheal intubation of the neonate. Primary outcome: pulse oxymetry value < 80% for more than 60 seconds. Secondary outcomes: number of attempts, duration of the procedure, changes in physiologic parameters, short- and long-term neurodevelopmental outcome. Hypothesis: "atropine + propofol" compared to "atropine+atracurium+sufentanil" will significantly reduce the frequency of severe hypoxemia.

Eligibility Criteria

Inclusion Criteria

  • Corrected age 3 seconds
  • Upper airway malformation
  • Life-threatening situation requiring immediate intubation
  • Inclusion in another trial not permitting any other participation
  • Impossibility to establish venous access
  • Any contra-indication to any experimental drug
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01490580). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search